KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Current Liabilities (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Total Current Liabilities data on record, last reported at $2.2 billion in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 115.92% year-over-year to $2.2 billion; the TTM value through Dec 2025 reached $2.2 billion, up 115.92%, while the annual FY2025 figure was $2.2 billion, 115.92% up from the prior year.
  • Total Current Liabilities reached $2.2 billion in Q4 2025 per JAZZ's latest filing, up from $1.0 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $2.2 billion in Q4 2025 and bottomed at $705.4 million in Q2 2022.
  • Average Total Current Liabilities over 5 years is $1.2 billion, with a median of $945.3 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: tumbled 32.42% in 2024, then surged 115.92% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $809.3 million in 2021, then grew by 15.31% to $933.2 million in 2022, then surged by 64.67% to $1.5 billion in 2023, then tumbled by 32.42% to $1.0 billion in 2024, then skyrocketed by 115.92% to $2.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $2.2 billion in Q4 2025, $1.0 billion in Q4 2024, and $1.6 billion in Q2 2024.